Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11423471 | 0.87 | ENPP1 (0.42) | HSD11B1SCN9AENPP1L3MBTL1MAPT | |
| SCHEMBL27660143 | 0.85 | KDM4E (0.46) | HSD11B1SCN9AL3MBTL1KDM4EMAPT | |
| SCHEMBL1045874 | 0.84 | FFAR4 (0.51) | HSD11B1SCN9AS1PR1L3MBTL1FFAR4 | |
| SCHEMBL19121718 | 0.79 | HSD11B1 (0.40) | HSD11B1SCN9AS1PR1L3MBTL1KDM4E | |
| SCHEMBL1043306 | 0.78 | GRIA1 (0.41) | HSD11B1SCN9AS1PR1ENPP1TRPA1 | |
| SCHEMBL15037483 | 0.73 | GPR3 (0.46) | SCN9AS1PR1FFAR4TRPA1 | |
| SCHEMBL29788132 | 0.71 | FFAR4 (0.55) | HSD11B1SCN9AL3MBTL1KDM4EMAPT | |
| SCHEMBL306822 | 0.71 | FFAR4 (0.55) | HSD11B1SCN9AL3MBTL1KDM4EMAPT | |
| SCHEMBL27784743 | 0.71 | MPL (0.40) | HSD11B1SCN9AS1PR1FFAR4TRPA1 | |
| SCHEMBL7701143 | 0.70 | ALDH1A1 (0.50) | HSD11B1SCN9AS1PR1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| CN-101277740-B | Antituberculous composition comprising azole compound | OTSUKA PHARMA CO LTD | 2012-12-05 | — | — | CN | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| WO-2007043542-A9 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HSD11B1 312/4885SCN9A 4350/4885S1PR1 2791/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HSD11B1 312/4885SCN9A 4350/4885S1PR1 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.